WO2013006761A3 - Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same - Google Patents

Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same Download PDF

Info

Publication number
WO2013006761A3
WO2013006761A3 PCT/US2012/045688 US2012045688W WO2013006761A3 WO 2013006761 A3 WO2013006761 A3 WO 2013006761A3 US 2012045688 W US2012045688 W US 2012045688W WO 2013006761 A3 WO2013006761 A3 WO 2013006761A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrroloquinolinyl
methods
pyrrolidine
preparing
same
Prior art date
Application number
PCT/US2012/045688
Other languages
French (fr)
Other versions
WO2013006761A2 (en
Inventor
Hiroshi Yamakose
Takafumi Kato
Original Assignee
Arqule, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2012278831A priority Critical patent/AU2012278831A1/en
Application filed by Arqule, Inc. filed Critical Arqule, Inc.
Priority to CA2839584A priority patent/CA2839584A1/en
Priority to EP12807740.1A priority patent/EP2729145A4/en
Priority to IN2443MUN2013 priority patent/IN2013MN02443A/en
Priority to CN201280043415.6A priority patent/CN103930110A/en
Priority to MX2014000253A priority patent/MX2014000253A/en
Priority to JP2014519316A priority patent/JP6073310B2/en
Priority to KR1020147001774A priority patent/KR20140146036A/en
Priority to BR112013033807A priority patent/BR112013033807A2/en
Publication of WO2013006761A2 publication Critical patent/WO2013006761A2/en
Publication of WO2013006761A3 publication Critical patent/WO2013006761A3/en
Priority to ZA2014/00108A priority patent/ZA201400108B/en
Priority to PH12015501980A priority patent/PH12015501980A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

The present invention provides pyrroloquinolinyl-pyrrole-2,5-dione formulations and methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of the formulations containing pyrroloquinolinyl-pyrrole-2,5-dione compounds.
PCT/US2012/045688 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same WO2013006761A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2014000253A MX2014000253A (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same.
CA2839584A CA2839584A1 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
EP12807740.1A EP2729145A4 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
IN2443MUN2013 IN2013MN02443A (en) 2011-07-07 2012-07-06
CN201280043415.6A CN103930110A (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
AU2012278831A AU2012278831A1 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
JP2014519316A JP6073310B2 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for their preparation and use
KR1020147001774A KR20140146036A (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
BR112013033807A BR112013033807A2 (en) 2011-07-07 2012-07-06 pyrroloquinolinyl-pyrrolidin-2,5-dione formulations and methods for their preparation
ZA2014/00108A ZA201400108B (en) 2011-07-07 2014-01-07 Pyrroloquinolinyl-pyrrolidine-2,5-dione for preparing and using same
PH12015501980A PH12015501980A1 (en) 2011-07-07 2015-09-07 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505175P 2011-07-07 2011-07-07
US61/505,175 2011-07-07

Publications (2)

Publication Number Publication Date
WO2013006761A2 WO2013006761A2 (en) 2013-01-10
WO2013006761A3 true WO2013006761A3 (en) 2013-04-18

Family

ID=47437711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/045688 WO2013006761A2 (en) 2011-07-07 2012-07-06 Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same

Country Status (14)

Country Link
US (2) US9180099B2 (en)
EP (1) EP2729145A4 (en)
JP (1) JP6073310B2 (en)
KR (1) KR20140146036A (en)
CN (1) CN103930110A (en)
AU (1) AU2012278831A1 (en)
BR (1) BR112013033807A2 (en)
CA (1) CA2839584A1 (en)
IN (1) IN2013MN02443A (en)
MX (1) MX2014000253A (en)
PH (1) PH12015501980A1 (en)
TW (1) TW201315470A (en)
WO (1) WO2013006761A2 (en)
ZA (1) ZA201400108B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846406T1 (en) * 2005-02-09 2011-02-28 Arqule Inc Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
AU2013252944B2 (en) 2012-04-23 2017-04-13 Arqule, Inc. Highly pure pyrroloquinolinyl-pyrrole-2,5-dione and pyrroloquinolinyl-pyrrolidine-2,5-dione and methods of preparing same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20100016597A1 (en) * 2007-04-06 2010-01-21 Activus Pharma Co., Ltd. Method for producing pulverized organic compound particle
US20100221251A1 (en) * 2005-02-09 2010-09-02 Arqule, Inc. Compositions and Methods for Treatment of Cancer
US20100297075A1 (en) * 2009-02-12 2010-11-25 Arqule, Inc. Combinational compositions and methods for treatment of cancer
US20110160242A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AU1560802A (en) * 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
UA89513C2 (en) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
JP5288791B2 (en) * 2005-01-28 2013-09-11 武田薬品工業株式会社 Miniaturized composition containing a hardly water-soluble substance
EP1897558B1 (en) 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP2009530415A (en) * 2006-03-20 2009-08-27 バーテックス ファーマシューティカルズ インコーポレイテッド Pharmaceutical composition
CN101474175B (en) * 2009-01-20 2014-07-02 重庆医药工业研究院有限责任公司 Oral solid preparation of Febuxostat with high-bioavailability and preparation method thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20100221251A1 (en) * 2005-02-09 2010-09-02 Arqule, Inc. Compositions and Methods for Treatment of Cancer
US20100016597A1 (en) * 2007-04-06 2010-01-21 Activus Pharma Co., Ltd. Method for producing pulverized organic compound particle
US20100297075A1 (en) * 2009-02-12 2010-11-25 Arqule, Inc. Combinational compositions and methods for treatment of cancer
US20110160242A1 (en) * 2009-12-23 2011-06-30 Arqule, Inc. Purified Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2729145A4 *

Also Published As

Publication number Publication date
JP2014518284A (en) 2014-07-28
TW201315470A (en) 2013-04-16
US20130011481A1 (en) 2013-01-10
US9180099B2 (en) 2015-11-10
WO2013006761A2 (en) 2013-01-10
KR20140146036A (en) 2014-12-24
EP2729145A2 (en) 2014-05-14
ZA201400108B (en) 2016-03-30
US20160022667A1 (en) 2016-01-28
PH12015501980A1 (en) 2017-10-18
CN103930110A (en) 2014-07-16
JP6073310B2 (en) 2017-02-01
MX2014000253A (en) 2014-10-17
EP2729145A4 (en) 2014-12-10
AU2012278831A1 (en) 2014-01-16
IN2013MN02443A (en) 2015-06-12
BR112013033807A2 (en) 2017-02-14
CA2839584A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2012155066A3 (en) Spiro-oxindole mdm2 antagonists
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
PH12014501108A1 (en) Anti-il-36r antibodies
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12014502406A1 (en) Anti-il-23p19 antibodies
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
AU2012265219A8 (en) Compounds containing hydrido-tricyano-borate anions
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX2015000428A (en) Compositions and methods for regulating car t cells.
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
TW201129570A (en) Spiro-oxindole MDM2 antagonists
WO2011082266A3 (en) Substituted heterocyclic compounds
MX2009013815A (en) Quinazolinone compounds and methods of use thereof.
ZA201307224B (en) (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 triazinyl bemzimidazoles, pahrmaceutical compositions containing them, and these compounds for use in treating proliferative deseases
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
EP2910246A4 (en) Pharmaceutical composition for preventing or treating cancer, containing enoblock as active ingredient
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
WO2012158493A3 (en) Compounds that bind to the erythropoietin receptor
WO2013090319A3 (en) Treatment of type i and type ii diabetes
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
WO2013013238A3 (en) Compounds and related compositions and methods of use
MX2013002446A (en) Substituted tetrahydropyrrolopyrazine derivatives.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2839584

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014519316

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/000253

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2012278831

Country of ref document: AU

Date of ref document: 20120706

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147001774

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012807740

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013033807

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 12015501980

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 112013033807

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131227